Melanoma News & Features
Nivolumab and dabrafenib plus trametinib up survival in melanoma without, with BRAF, respectively.
There may be a correlation between tumor necrosis factor (TNF)-alpha inhibitors and the development of uveal melanoma.
Treatment with a combination of the drugs sargramostim plus ipilimumab, rather than ipilimumab alone, yielded longer overall survival and lower toxicity for patients with metastatic melanoma.
Pairing ipilimumab with sargramostim gives patients about five extra months survival time for patients with advanced melanoma, researchers report.
A gigapixel camera that takes high-resolution snapshots of the entire body could prove to be a new tool for whole-body skin cancer screening.
Sign Up for Free e-newsletters
- Risk prediction improved by new classification in chronic lymphocytic leukemia
- Treatment options for HER2-positive breast cancer
- Antimicrobial agent triclosan, used in soaps and detergents, may cause cancer
- The Society for Integrative Oncology (SIO) and co-researchers issue a report card on complementary therapies for breast cancer
- Disparities in non-small cell lung cancer (NSCLC) treatment based on race, treatment center
- A New Era is Coming up in the Treatment of Chronic Lymphocytic Leukemia
- Early palliative care can cut hospital readmissions for cancer patients
- ONA Interview: Breaking the barriers to effective palliative care
- Fluorescent tattoos may improve self-esteem in patients receiving radiotherapy for breast cancer
- Cancer prehabilitation: One step toward improved outcomes
- Combination treatments show promise for metastatic melanoma
- Helper therapy principle may not be helpful for breast cancer
- Inadequately management of hot flushes leave women vulnerable
- Metformin use may be associated with decreased risk of prostate cancer
- TNF-alpha inhibitors associated with uveal melanoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|